Navigation Links
MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 33rd Annual Deutsche Bank Healthcare Conference
Date:4/28/2008

CORAL GABLES, Fla., April 28 /PRNewswire-FirstCall/ -- MBF Healthcare Acquisition Corp. (Amex: MBH), a publicly traded special purpose acquisition company, announced today that it and Critical Homecare Solutions Holdings, Inc. ("CHS"), a privately-owned, leading provider of comprehensive home infusion therapy and specialty infusion services, are scheduled to present on Monday, May 5, 2008 at the 33rd Annual Deutsche Bank Healthcare Conference in Boston, MA. On February 6, 2008, MBH signed a definitive stock purchase agreement with CHS. Presenting at the conference from CHS will be Bob Cucuel, President and Chief Executive Officer, and MJ Graves, Chief Financial Officer.

Event: Deutsche Bank Health Care Conference

Date: Monday, May 5, 2008

Time: 4:00 p.m. ET

Place: The InterContinental Boston, Boston, MA

An audio Web cast of the presentation will be on the investor relations section of the CHS website at http://www.criticalhs.com. A replay of the presentation will be available for 15 days.

About MBF Healthcare Acquisition Corp.

MBH is a blank check company formed for the purpose of acquiring, through a merger, capital stock exchange, stock purchase, asset acquisition or other similar business combination, one or more operating business in the healthcare industry.

About Critical Homecare Solutions Holdings, Inc.

CHS is a leading provider of comprehensive home infusion therapy and specialty infusion services to patients suffering from acute or chronic conditions. CHS delivers over 400,000 infusion pharmaceuticals, biopharmaceuticals, nutrients and related services each year to patients in the home through 33 infusion locations in 14 states, primarily in the eastern United States. CHS also provides over 350,000 nursing and therapy visits and 500,000 private duty nursing hours each year to patients in the home through 32 home nursing locations in three states. CHS currently provides customized local clinical care to over 19,000 patients through its branch network and has relationships with approximately 450 payors, including insurers, managed care organizations and government payors. For more information on CHS please visit the company website at (http://www.criticalhs.com). The information included on the CHS website is not incorporated by reference into this press release or in any filing with the Securities and Exchange Commission.

Additional Information and Where to Find It

On April 1, 2008, MBH filed an amended preliminary proxy statement concerning the previously announced proposed transaction between MBH and CHS, which will be subject to review by the Securities and Exchange Commission. MBH stockholders and other interested persons are urged to read the definitive proxy statement and other relevant materials when they become available as they will contain important information about MBH, CHS and the proposed transaction. Such persons can also read MBH's final prospectus dated April 17, 2007, for a description of the security holdings of the MBH officers and directors and their respective interests in the successful consummation of the proposed transaction. The definitive proxy statement will be mailed to stockholders as of a record date to be established for voting on the proposed transaction.

Participants in Solicitation

MBH and its directors and executive officers and CHS and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of MBH stock in respect of the proposed transaction. Investors may obtain additional information regarding the interest of such participants by reading the proxy statement relating to the proposed transaction and MBH's Annual Report on Form 10-K for its fiscal year ended December 31, 2007.

Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined by the United States Private Securities Litigation Reform Act of 1995. Any such forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations such as material adverse events affecting MBH and CHS, their ability to complete a business combination and those other risks and uncertainties detailed in their filings with the Securities and Exchange Commission. MBH and CHS caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. MBH and CHS do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based.

Contacts:

Stephanie Carrington/Jared Hoffman

The Ruth Group

646-536-7017 / 7013

scarrington@theruthgroup.com

jhoffman@theruthgroup.com


'/>"/>
SOURCE MBF Healthcare Acquisition Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
2. Inverness Medical Innovations to Participate at Morgan Stanley Global Healthcare Unplugged Conference on April 30, 2008
3. Isolagen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
5. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
8. NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
9. BioMarin to Present at the Morgan Stanley Healthcare Conference
10. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Biodel Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference April 30th 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, ... executives and entrepreneurs, held The Future of San Diego Life Science event at the ... life science community attended the event with speakers Dr. Rich Heyman, former CEO of ...
(Date:5/23/2016)... Texas (PRWEB) , ... May 23, 2016 , ... The need for blood donations in ... this week by the South Texas Blood & Tissue Center, blood donations are on the ... 30 years, and they are down 21 percent in South Texas in the last four ...
(Date:5/23/2016)... WARSAW, Ind. , May 23, 2016 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the second quarter of 2016. ... on or about July 29, 2016 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
(Date:5/23/2016)... LONDON , May 23, 2016 - ... by 40% - Frontage Implement a Single Platform to ... Compliance and Traceability Within the Bioanalytical lab Frontage Laboratories, ... the United States and China , ... its laboratory facilities. In addition to serving as the global electronic ...
Breaking Biology Technology:
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® , ... enrollment solutions, today announced the addition of smart ... Altus multi-factor authentication platform. New contextual and ... to step-up security where it,s needed most — ... Washington, DC . --> ...
(Date:3/3/2016)... 3, 2016  FlexTech, a SEMI Strategic Association Partner, ... Research & Development, Leadership in Education, and, in a ... 9 th year of the FLEXI Awards and ... individuals from past years . Judging was done ... set of criteria, by a panel of non-affiliated, independent, ...
(Date:3/3/2016)... DE SOTO, Kansas , March 3, 2016 /PRNewswire/ ... offer Oncimmune,s Early CDT®-Lung, a blood test to ... lung cancer Early CDT®-Lung test to its ... --> Early CDT®-Lung test to its clients which ... Oncimmune, a leader in early cancer detection, today announced ...
Breaking Biology News(10 mins):